Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer
October 20th 2023The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.
Read More
Study Results Indicate Precision Therapies Make Up Approximately Half of FDA-Approved Oncology Drugs
October 19th 2023This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.
Read More
Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
October 19th 2023The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Read More